| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0895-4356(98)00151-6 |
| P8608 | Fatcat ID | release_tz2f5uhscbewvmdv7fpiysqbvi |
| P698 | PubMed publication ID | 10210244 |
| P2093 | author name string | Matchar DB | |
| Parmigiani G | |||
| Samsa GP | |||
| Lipscomb J | |||
| Ancukiewicz M | |||
| Abrahamse P | |||
| Reutter RA | |||
| P2860 | cites work | Cost effectiveness of screening perimenopausal white women for osteoporosis: bone densitometry and hormone replacement therapy | Q68355279 |
| Disability and use of rehabilitation services following stroke in Rochester, Minnesota, 1975-1979 | Q69251417 | ||
| Forecasting coronary heart disease incidence, mortality, and cost: the Coronary Heart Disease Policy Model | Q69414455 | ||
| Loss of arm function after stroke: measurement, frequency, and recovery | Q69723953 | ||
| Recovery from physical disability after stroke: normal patterns as a basis for evaluation | Q69893462 | ||
| The rate of recovery from stroke - and its measurement | Q71084475 | ||
| Patient preferences for stroke outcomes | Q72157125 | ||
| Disablement and quality of life after stroke | Q72823964 | ||
| Recovery after stroke--the first 3 months | Q24515370 | ||
| Tissue plasminogen activator for acute ischemic stroke | Q29619377 | ||
| Multi-attribute health status classification systems. Health Utilities Index | Q33569094 | ||
| Recovery after stroke | Q33618350 | ||
| Arm function after stroke: measurement and recovery over the first three months | Q33628597 | ||
| Cerebral vascular accidents in patients over the age of 60. II. Prognosis | Q34241339 | ||
| What role do neurologists play in determining the costs and outcomes of stroke patients? | Q36830401 | ||
| The Stroke Prevention Patient Outcomes Research Team. Goals and methods | Q40784074 | ||
| Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction | Q40985280 | ||
| Cost-effectiveness of screening for asymptomatic carotid atherosclerotic disease | Q41194083 | ||
| Methodologic issues in policy modeling for cardiovascular disease | Q41225068 | ||
| Assessing uncertainty in cost-effectiveness analyses: application to a complex decision model. | Q41620832 | ||
| The Stroke Prevention Policy Model: linking evidence and clinical decisions | Q41650619 | ||
| Similar motor recovery of upper and lower extremities after stroke | Q48108415 | ||
| Utilities for major stroke: results from a survey of preferences among persons at increased risk for stroke. | Q50861926 | ||
| The profile of recovery from stroke and factors influencing outcome. | Q51229357 | ||
| Statistical inference for cost-effectiveness ratios. | Q52265200 | ||
| Confidence intervals for cost-effectiveness ratios: an application of Fieller's theorem. | Q52302060 | ||
| Estimating confidence intervals for cost-effectiveness ratios: an example from a randomized trial. | Q52889717 | ||
| Adjusting for bias in C/E ratio estimates. | Q52891078 | ||
| Knowledge of risk among patients at increased risk for stroke. | Q53598114 | ||
| Assessment of rehabilitation technologies in stroke. Outcomes and costs. | Q53652189 | ||
| Costs, effects and C/E-ratios alongside a clinical trial. | Q53658625 | ||
| Cost-effectiveness analysis of patient management alternatives after uncomplicated myocardial infarction: a model. | Q54080516 | ||
| Recovery of motor function after stroke | Q67985917 | ||
| P433 | issue | 3 | |
| P921 | main subject | randomized experiment | Q1231081 |
| cost-effectiveness analysis | Q1754768 | ||
| P304 | page(s) | 259-271 | |
| P577 | publication date | 1999-03-01 | |
| P1433 | published in | Journal of Clinical Epidemiology | Q6294959 |
| P1476 | title | Performing cost-effectiveness analysis by integrating randomized trial data with a comprehensive decision model: application to treatment of acute ischemic stroke | |
| P2283 | uses | randomized experiment | Q1231081 |
| P478 | volume | 52 |
| Q51984621 | A Bayesian approach to net health benefits: an illustration and application to modeling HIV prevention. |
| Q35056737 | A meta-analysis of quality-of-life estimates for stroke |
| Q36685755 | A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke |
| Q74237119 | Aspirin plus extended-release dipyridamole or clopidogrel compared with aspirin monotherapy for the prevention of recurrent ischemic stroke: a cost-effectiveness analysis |
| Q36381197 | Bayesian methods for evidence synthesis in cost-effectiveness analysis |
| Q24811660 | Combining information from multiple data sources to create multivariable risk models: illustration and preliminary assessment of a new method |
| Q38628170 | Cost-Effectiveness Analysis of Microscopic and Endoscopic Transsphenoidal Surgery Versus Medical Therapy in the Management of Microprolactinoma in the United States |
| Q35779416 | Cost-Effectiveness of Intra-Arterial Treatment as an Adjunct to Intravenous Tissue-Type Plasminogen Activator for Acute Ischemic Stroke |
| Q33772349 | Cost-Effectiveness of Solitaire Stent Retriever Thrombectomy for Acute Ischemic Stroke: Results From the SWIFT-PRIME Trial (Solitaire With the Intention for Thrombectomy as Primary Endovascular Treatment for Acute Ischemic Stroke). |
| Q77146377 | Cost-Utility analysis of tissue plasminogen activator therapy for acute ischaemic stroke: a Canadian healthcare perspective |
| Q33600851 | Cost-effectiveness of CT perfusion for selecting patients for intravenous thrombolysis: a US hospital perspective. |
| Q50115948 | Cost-effectiveness of ancrod treatment of acute ischaemic stroke: results from the Stroke Treatment with Ancrod Trial (STAT). |
| Q40208277 | Cost-effectiveness of computed tomographic angiography in screening for aneurysm in spontaneous subarachnoid hemorrhage |
| Q38091297 | Cost-effectiveness of digital subtraction angiography in the setting of computed tomographic angiography negative subarachnoid hemorrhage. |
| Q36780434 | Cost-effectiveness of echocardiography to identify intracardiac thrombus among patients with first stroke or transient ischemic attack |
| Q53841672 | Cost-effectiveness of mechanical thrombectomy within 6 hours of acute ischaemic stroke in China. |
| Q39862309 | Cost-effectiveness of stent-retriever thrombectomy in combination with IV t-PA compared with IV t-PA alone for acute ischemic stroke in the UK. |
| Q34374190 | Cost-effectiveness of thrombolysis within 4.5 hours of acute ischemic stroke in China |
| Q35187798 | Cost-effectiveness of tissue-type plasminogen activator in the 3- to 4.5-hour time window for acute ischemic stroke. |
| Q34772261 | Cost-effectiveness of transfers to centers with neurological intensive care units after intracerebral hemorrhage |
| Q35040678 | Decision analytical economic modelling within a Bayesian framework: application to prophylactic antibiotics use for caesarean section. |
| Q33903387 | Development of WHO guidelines on generalized cost-effectiveness analysis |
| Q35767707 | Different Imaging Strategies in Patients With Possible Basilar Artery Occlusion: Cost-Effectiveness Analysis |
| Q44565540 | Economic implications of nesiritide versus dobutamine in the treatment of patients with acutely decompensated congestive heart failure |
| Q47192297 | Endovascular Thrombectomy for Ischemic Stroke Increases Disability-Free Survival, Quality of Life, and Life Expectancy and Reduces Cost |
| Q36359124 | Evidence synthesis, parameter correlation and probabilistic sensitivity analysis |
| Q35172539 | How should stroke services be organised? |
| Q38196603 | Illicit and pharmaceutical drug consumption estimated via wastewater analysis. Part B: placing back-calculations in a formal statistical framework. |
| Q36462959 | Impact of functional status at six months on long term survival in patients with ischaemic stroke: prospective cohort studies |
| Q37979874 | Intravenous thrombolysis for acute ischemic stroke in Asia |
| Q52024862 | Measuring uncertainty in complex decision analysis models. |
| Q37666143 | Microvascular Decompression Versus Stereotactic Radiosurgery for Trigeminal Neuralgia: A Decision Analysis |
| Q37711254 | Modeling stroke management: a qualitative review of cost-effectiveness analyses |
| Q35913167 | Modeling the Cost Effectiveness of Neuroimaging-Based Treatment of Acute Wake-Up Stroke |
| Q40028428 | Multiparameter evidence synthesis in epidemiology and medical decision-making |
| Q61812712 | Personalized Prehospital Triage in Acute Ischemic Stroke |
| Q28298648 | Plant stanol esters are potentially cost-effective in the prevention of coronary heart disease in men: Bayesian modelling approach |
| Q37457094 | Quantifying the value of stroke disability outcomes: WHO global burden of disease project disability weights for each level of the modified Rankin Scale |
| Q37244517 | Stroke and thrombolysis in developing countries |
| Q36886256 | The contrast and convergence of Bayesian and frequentist statistical approaches in pharmacoeconomic analysis |
| Q35416797 | The cost-effectiveness of telestroke in the treatment of acute ischemic stroke |
| Q33593063 | Thrombolysis ImPlementation in Stroke (TIPS): evaluating the effectiveness of a strategy to increase the adoption of best evidence practice--protocol for a cluster randomised controlled trial in acute stroke care |
| Q46125977 | Time Course of Evolution of Disability and Cause-Specific Mortality After Ischemic Stroke: Implications for Trial Design |
| Q40867521 | Utility analysis of management strategies for suspected subarachnoid haemorrhage in patients with thunderclap headache with negative CT result |
| Q44417485 | Which approach to anticoagulation management is best? Illustration of an interactive mathematical model to support informed decision making |
| Q40349299 | Whither trial-based economic evaluation for health care decision making? |
Search more.